atai Wins $11.4M NIDA Grant to Develop Non-Hallucinogenic Psychedelics for OUD • Australia’s Largest Private Health Insurer Funds Psilocybin for Treatment-Resistant Depression Pilot • Osmind and Bendable Share Real-World Outcomes from 88 Psilocybin Clients • Psychedelic Pipeline Bullseye Chart Update Log • Pennsylvania Lawmakers Talk Psychedelics in Hearing on Treatment-Resistant Depression • Reunion Upsizes Series A to $133M Following Phase 2 Success • Virtual Ketamine Startup ...| Psychedelic Alpha
Psychedelic CEOs’ FDA Wish-List • APA Division 56 President Jessica Punzo on Psychologists and Psychedelics • Compass’ Phase 2 PTSD Study Published • Cybin Ousts CEO Doug Drysdale • DoD to Test Military for Psilocybin • MindMed's Phase 2b LSD for GAD Study Publishes • and more..| Psychedelic Alpha